To systematically evaluate the efficacy of Niaoduqing Granules combined with ACEI/ARB in the treatment of diabetic nephropathy.Methods:Computer-researched literature on diabetic nephropathy randomized controlled trials ( RCT ) in the treatment of Niaoduqing Granules combined with ACEI/ARB was screened in CNKI,Wanfang,VIP,Pubmed,Embase,and Cochrane Library.A Meta-analysis of the data required in the literature in accordance with this study was performed using revman 5.3 software.Results:A total of 15 randomized controlled trials were finally analyzed and 1 063 patients were adopted for analysis,including 538 patients receiving the combination treatment and 525 patients in the control group.The results of Meta-analysis showed that the clinical remission rate of Niaoduqing Granule combined with ACEI/ARB was significantly better than of the control group [OR=2.92,95% CI ( 1.76-4.86 )].The treatment combined with Niaoduqing granule decreased the 24-hour urinary protein quantitation [MD 0.71,95% CI ( 0.28-1.14 )] and UAER [MD 41.13,95% CI ( 26.66-55.59 )] levels.However,the combination group had no treatment advantage on reducing serum urea nitrogen [MD 0.86,95% CI ( 0.05-1.68 ),P=0.02] and fasting blood glucose ( MD-0.03,95% CI (-0.15-0.09 ),P=0.61].And there was no significance in adverse events between 2 groups [RR=2.34,95% CI ( 0.69-7.95 ),P=0.17].Conclusion:Niaoduqing Granules-ACEI/ARB combination group maybe as safe as using ACEI/ARB alone,and the combination had an advantage in improvement in total effective rate,reducing of 24-hour urinary protein quantitation and UAER.However,due to the low quality of the literature included in this analysis,more centers and large samples are needed in the future.A more rigorous randomized double-blind trial was designed for further validation.